-
★
Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
(Hinzugefügt: 17.08.2022 um 10:33 Uhr)
https://ir.novavax.com/2022-08-15-Novavax-Submits-Application-to-the-U-S-FDA-for-Emergency-Use-Authorization-for-Novavax-COVID-19-Vaccine,-Adjuvanted-as-a-Booster-in-Adults-Aged-18-and-Older
-
★
US-Arzneimittelbehörde »besorgt« wegen möglichen Risikos bei Novavax
(Hinzugefügt: 05.06.2022 um 15:24 Uhr)
https://www.spiegel.de/wissenschaft/corona-impfung-us-arzneimittelbehoerde-besorgt-wegen-moeglichem-myokarditis-risiko-bei-novavax-a-258466bd-449e-4db8-bb58-6d9636bae674
-
★
PROTEINIMPFSTOFF NVX-COV2373 (NUVAXOVID) GEGEN SARS-COV-2
(Hinzugefügt: 19.02.2022 um 13:35 Uhr)
https://www.arznei-telegramm.de/html/2022_02/2202012_01.html
-
★
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
(Hinzugefügt: 01.07.2021 um 08:40 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2107659
-
★
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
(Hinzugefügt: 06.05.2021 um 09:11 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2103055
-
MYOKARDITIS/PERIKARDITIS UNTER PROTEINBASIERTEM SARS-COV-2-IMPFSTOFF NVX-COV2373 (NUVAXOVID)
(Hinzugefügt: 28.12.2022 um 14:37 Uhr)
https://www.arznei-telegramm.de/html/2022_08/2208063_02.html
-
Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
(Hinzugefügt: 19.11.2022 um 19:28 Uhr)
https://www.biorxiv.org/content/10.1101/2022.07.14.500148v1
-
MYOKARDITIS/PERIKARDITIS UNTER PROTEINBASIERTEM SARS-COV-2-IMPFSTOFF NVX-COV2373 (NUVAXOVID)
(Hinzugefügt: 10.11.2022 um 13:46 Uhr)
https://www.arznei-telegramm.de/html/2022_06/2206048_02.html
-
Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages
(Hinzugefügt: 30.10.2022 um 09:39 Uhr)
https://www.biorxiv.org/content/10.1101/2022.07.14.500148v1
-
MYOKARDITIS/PERIKARDITIS UNTER PROTEINBASIERTEM SARS-COV-2-IMPFSTOFF NVX-COV2373 (NUVAXOVID)
(Hinzugefügt: 24.06.2022 um 09:51 Uhr)
https://www.arznei-telegramm.de/html/2022_06/2206048_02.html
-
Wenige Verdachtsmeldungen auf Impfnebenwirkungen, keine Todesfälle bei Nuvaxovid
(Hinzugefügt: 10.05.2022 um 08:31 Uhr)
https://www.aerzteblatt.de/nachrichten/133937/Wenige-Verdachtsmeldungen-auf-Impfnebenwirkungen-keine-Todesfaelle-bei-Nuvaxovid
-
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial
(Hinzugefügt: 10.05.2022 um 08:25 Uhr)
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00041-8/fulltext
-
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
(Hinzugefügt: 26.04.2022 um 13:02 Uhr)
https://ir.novavax.com/2022-04-22-Novavax-Announces-Initiation-of-COVID-19-Vaccine-Booster-Study-in-Adolescents-in-Phase-3-PREVENT-19-Trial?sf163761994=1
-
Der Impfstoff Nuvaxovid (Novavax) zur Impfung gegen Corona
(Hinzugefügt: 21.02.2022 um 16:29 Uhr)
https://www.gesundheitsinformation.de/der-impfstoff-nuvaxovid-novavax-zur-impfung-gegen-corona.html
-
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
(Hinzugefügt: 17.02.2022 um 06:59 Uhr)
https://ir.novavax.com/2022-01-31-Novavax-Submits-Request-to-the-U-S-FDA-for-Emergency-Use-Authorization-of-COVID-19-Vaccine
-
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(Hinzugefügt: 17.02.2022 um 06:09 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.23.21267374v1
-
Neue STIKO-Empfehlung: Nuvaxovid aufgenommen, zweite Boosterung für bestimmte Gruppen
(Hinzugefügt: 15.02.2022 um 16:41 Uhr)
https://www.aerzteblatt.de/nachrichten/131836/Neue-STIKO-Empfehlung-Nuvaxovid-aufgenommen-zweite-Boosterung-fuer-bestimmte-Gruppen
-
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
(Hinzugefügt: 14.02.2022 um 15:43 Uhr)
https://ir.novavax.com/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial
-
COVID-19: Novavax-Impfstoff erzielt auch bei Jugendlichen hohe Schutzwirkung
(Hinzugefügt: 14.02.2022 um 15:38 Uhr)
https://www.aerzteblatt.de/nachrichten/131736/COVID-19-Novavax-Impfstoff-erzielt-auch-bei-Jugendlichen-hohe-Schutzwirkung
-
Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial
(Hinzugefügt: 26.12.2021 um 10:46 Uhr)
https://www.medrxiv.org/content/10.1101/2021.12.23.21267374v1
-
KV-Chef: Neuer Impfstoff könnte Impfquote deutlich erhöhen
(Hinzugefügt: 23.12.2021 um 20:27 Uhr)
https://www.aerzteblatt.de/nachrichten/130286/KV-Chef-Neuer-Impfstoff-koennte-Impfquote-deutlich-erhoehen
-
Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
(Hinzugefügt: 23.12.2021 um 19:57 Uhr)
https://ir.novavax.com/2021-12-21-Novavax-Announces-Initiation-of-PREVENT-19-COVID-19-Vaccine-Phase-3-Trial-Booster-Study?sf157114423=1
-
https://www.aerzteblatt.de/nachrichten/130323/WHO-genehmigt-Novavax-Impfstoff-als-Coronavakzin
(Hinzugefügt: 23.12.2021 um 19:50 Uhr)
https://www.aerzteblatt.de/nachrichten/130323/WHO-genehmigt-Novavax-Impfstoff-als-Coronavakzin
-
Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies
(Hinzugefügt: 23.12.2021 um 19:41 Uhr)
https://ir.novavax.com/2021-12-22-Novavax-Announces-Initial-Omicron-Cross-Reactivity-Data-from-COVID-19-Vaccine-Booster-and-Adolescent-Studies
-
EMA recommends Nuvaxovid for authorisation in the EU
(Hinzugefügt: 21.12.2021 um 12:49 Uhr)
https://www.ema.europa.eu/en/news/ema-recommends-nuvaxovid-authorisation-eu
-
Novavax Receives Positive European Medicines Agency Recommendation for Conditional Marketing Authorization of its COVID-19 Vaccine
(Hinzugefügt: 20.12.2021 um 16:36 Uhr)
https://ir.novavax.com/2021-12-20-Novavax-Receives-Positive-European-Medicines-Agency-Recommendation-for-Conditional-Marketing-Authorization-of-its-COVID-19-Vaccine?sf157012621=1
-
Novavax: EMA macht Weg frei, EU-Kommission erteilt Zulassung
(Hinzugefügt: 20.12.2021 um 16:34 Uhr)
https://www.aerzteblatt.de/nachrichten/130246/Novavax-Weg-frei-fuer-die-Zulassung-in-der-EU
-
SARS-CoV-2: Novavax-Impfstoff in Phase-3-Studie hoch effektiv
(Hinzugefügt: 18.12.2021 um 14:13 Uhr)
https://www.aerzteblatt.de/nachrichten/130141/SARS-CoV-2-Novavax-Impfstoff-in-Phase-3-Studie-hoch-effektiv
-
NOVAVAX UND VALNEVA IM VERGLEICH: EXPERTE ERKENNT VORTEIL IN DIESEM MPFSTOFF
(Hinzugefügt: 17.12.2021 um 14:08 Uhr)
https://www.echo24.de/welt/novavax-valneva-totimpfstoff-corona-impfstoff-impfskeptiker-studien-zulassung-experte-vergleich-91177996.html
-
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
(Hinzugefügt: 17.12.2021 um 13:12 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2116185
-
Novavax Statement on PREVENT-19 Phase 3 Clinical Trial Results Publication in the New England Journal of Medicine
(Hinzugefügt: 17.12.2021 um 13:12 Uhr)
https://ir.novavax.com/Novavax-Statement-on-PREVENT-19-Phase-3-Clinical-Trial-Results-Publication-in-the-New-England-Journal-of-Medicine
-
Corona: EMA will vor Weihnachten über Novavax entscheiden
(Hinzugefügt: 17.12.2021 um 09:33 Uhr)
https://www.aerzteblatt.de/nachrichten/130158/Corona-EMA-will-vor-Weihnachten-ueber-Novavax-entscheiden
-
Covid-19: Whatever happened to the Novavax vaccine?
(Hinzugefügt: 13.12.2021 um 11:19 Uhr)
https://www.bmj.com/content/375/bmj.n2965
-
Corona-Impfstoff Novavax: Zulassung erneut verschoben – Das ist der Grund
(Hinzugefügt: 06.12.2021 um 13:13 Uhr)
https://www.fr.de/panorama/novavax-totimpfstoff-corona-impfung-proteinbasiert-covid-19-wann-kommt-freigabe-usa-91159288.html
-
Corona-Totimpfstoff von Novavax: Wann kommt die Zulassung?
(Hinzugefügt: 03.12.2021 um 17:44 Uhr)
https://www.fr.de/wissen/novavax-totimpfstoff-zulassung-corona-vakzin-impfung-virus-pandemie-news-91140226.html
-
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
(Hinzugefügt: 25.11.2021 um 18:49 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00409-4/fulltext
-
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
(Hinzugefügt: 19.11.2021 um 21:04 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00409-4/fulltext
-
How protein-based COVID vaccines could change the pandemic
(Hinzugefügt: 19.11.2021 um 15:56 Uhr)
https://www.nature.com/articles/d41586-021-03025-0
-
Corona-Impfstoff von Novavax: Was er kann, wie er funktioniert
(Hinzugefügt: 19.11.2021 um 15:36 Uhr)
https://www.br.de/nachrichten/wissen/corona-impfstoff-von-novavax-wie-er-funktioniert-und-was-er-kann,SgLqtCO
-
EMA receives application for conditional marketing authorisation of Novavax’s COVID-19 vaccine, Nuvaxovid
(Hinzugefügt: 19.11.2021 um 15:30 Uhr)
https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-novavaxs-covid-19-vaccine-nuvaxovid
-
Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization
(Hinzugefügt: 19.11.2021 um 15:29 Uhr)
https://ir.novavax.com/2021-11-17-Novavax-Confirms-European-Medicines-Agency-Review-of-COVID-19-Vaccine-Filing-for-Conditional-Marketing-Authorization
-
USA erkennt Teilnehmer an Novavax-Phase-3-Studien als vollständig geimpft an
(Hinzugefügt: 19.11.2021 um 15:29 Uhr)
https://www.pharma-food.de/markt/usa-erkennt-teilnehmer-an-novavax-phase-3-studien-als-vollstaendig-geimpft-an-532.html
-
Novavax beantragt EU-Zulassung für seinen Coronaimpfstoff
(Hinzugefügt: 19.11.2021 um 15:27 Uhr)
https://www.aerzteblatt.de/nachrichten/129203/Novavax-beantragt-EU-Zulassung-fuer-seinen-Coronaimpfstoff
-
Indonesien lässt als erstes Land Coronaimpfstoff von Novavax zu
(Hinzugefügt: 04.11.2021 um 08:55 Uhr)
https://www.aerzteblatt.de/nachrichten/128682/Indonesien-laesst-als-erstes-Land-Coronaimpfstoff-von-Novavax-zu?googlenews=1
-
Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom
(Hinzugefügt: 29.10.2021 um 13:40 Uhr)
https://ir.novavax.com/2021-10-27-Novavax-Files-for-Authorization-of-its-COVID-19-Vaccine-in-the-United-Kingdom
-
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
(Hinzugefügt: 18.10.2021 um 10:07 Uhr)
https://www.medrxiv.org/content/10.1101/2021.10.05.21264567v1
-
Eine neue Art Corona-Impfstoff
(Hinzugefügt: 18.10.2021 um 09:52 Uhr)
https://www.apotheken-umschau.de/krankheiten-symptome/infektionskrankheiten/coronavirus/novavax-eine-neue-art-corona-impfstoff-799237.html
-
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults
(Hinzugefügt: 18.10.2021 um 09:42 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.26.21252482v1
-
Clinical trialists to be offered 'top-up' vaccine doses
(Hinzugefügt: 12.10.2021 um 10:41 Uhr)
https://www.gov.uk/government/news/clinical-trialists-to-be-offered-top-up-vaccine-doses
-
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
(Hinzugefügt: 20.09.2021 um 09:23 Uhr)
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00263-9
-
Novavax to Participate in University of Oxford Com-COV3 Study Comparing Mixed COVID-19 Vaccine Schedule in Adolescents
(Hinzugefügt: 19.09.2021 um 14:52 Uhr)
https://ir.novavax.com/2021-09-16-Novavax-to-Participate-in-University-of-Oxford-Com-COV3-Study-Comparing-Mixed-COVID-19-Vaccine-Schedule-in-Adolescents
-
Novavax könnte schon bald in der EU zugelassen werden. Das Mittel funktioniert anders als Biontech und Co.
(Hinzugefügt: 14.09.2021 um 07:46 Uhr)
https://www.morgenpost.de/vermischtes/article233250287/novavax-biontech-moderna-covid-19-impfstoff-studie.html
-
Was kann der Corona-Impfstoff von Novavax?
(Hinzugefügt: 24.08.2021 um 16:36 Uhr)
https://www.br.de/nachrichten/wissen/corona-impfstoff-von-novavax-wie-er-funktioniert-und-was-er-kann,SgLqtCO?fbclid=IwAR23BLiV2nAo4PxU5CARDMG6RlghqGD9ArcbNm_JXr1N7y59VrmFdRNHu1s
-
Novavax again delays seeking U.S. approval for COVID-19 vaccine
(Hinzugefügt: 07.08.2021 um 16:01 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-again-delays-seeking-us-approval-covid-19-vaccine-2021-08-05/
-
EU sichert Kauf von bis zu 200 Million Dosen Novavax-Impfstoff
(Hinzugefügt: 06.08.2021 um 11:27 Uhr)
https://www.aerzteblatt.de/nachrichten/126149/EU-sichert-Kauf-von-bis-zu-200-Million-Dosen-Novavax-Impfstoff
-
Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination
(Hinzugefügt: 06.08.2021 um 10:47 Uhr)
https://ir.novavax.com/2021-08-05-Novavax-Announces-COVID-19-Vaccine-Booster-Data-Demonstrating-Four-Fold-Increase-in-Neutralizing-Antibody-Levels-Versus-Peak-Responses-After-Primary-Vaccination
-
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
(Hinzugefügt: 01.07.2021 um 08:38 Uhr)
https://ir.novavax.com/2021-06-30-Novavax-Publishes-Results-of-United-Kingdom-Phase-3-Clinical-Trial-in-New-England-Journal-of-Medicine,-Demonstrating-High-Levels-of-Efficacy-of-COVID-19-Vaccine
-
The mRNA Vaccines Are Extraordinary, but Novavax Is Even Better
(Hinzugefügt: 30.06.2021 um 15:22 Uhr)
https://www.theatlantic.com/health/archive/2021/06/novavax-now-best-covid-19-vaccine/619276/
-
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
(Hinzugefügt: 20.06.2021 um 18:03 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and
-
Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines
(Hinzugefügt: 20.06.2021 um 18:02 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.09.21258556v1
-
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
(Hinzugefügt: 20.06.2021 um 17:56 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-results-first-study-influenza-vaccine
-
The Novavax Vaccine Data, and Spike Proteins in General
(Hinzugefügt: 20.06.2021 um 17:51 Uhr)
https://blogs.sciencemag.org/pipeline/archives/2021/06/15/the-novavax-vaccine-data-and-spike-proteins-in-general
-
Neuer Vakzintyp Studie: Neuer Corona-Impfstoff von US-Hersteller hochwirksam
(Hinzugefügt: 14.06.2021 um 16:28 Uhr)
https://www.t-online.de/nachrichten/panorama/id_90219470/novavax-neuer-corona-impfstoff-von-us-hersteller-laut-studie-hochwirksam.html
-
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
(Hinzugefügt: 14.06.2021 um 05:29 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-data-three-complementary-studies
-
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
(Hinzugefügt: 16.05.2021 um 10:12 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.13.21256639v1
-
Novavax verschiebt Zulassungsantrag für seinen Coronaimpfstoff
(Hinzugefügt: 12.05.2021 um 07:51 Uhr)
https://www.aerzteblatt.de/nachrichten/123762/Novavax-verschiebt-Zulassungsantrag-fuer-seinen-Coronaimpfstoff
-
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
(Hinzugefügt: 11.05.2021 um 07:07 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-preclinical-data-combination
-
Novavax delays timelines for COVID-19 vaccine regulatory filings, production
(Hinzugefügt: 11.05.2021 um 06:56 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-expects-covid-19-vaccine-us-data-trial-q2-2021-05-10/
-
Novavax to seek US authorization of its Covid-19 vaccine in third quarter, CEO says
(Hinzugefügt: 11.05.2021 um 06:54 Uhr)
https://edition.cnn.com/2021/05/10/health/novavax-covid-19-vaccine-authorization-third-quarter-bn/index.html
-
Novavax vaccine shows 51% efficacy against South African variant, study finds
(Hinzugefügt: 06.05.2021 um 09:08 Uhr)
https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-vaccine-shows-43-efficacy-against-south-african-variant-study-finds-2021-05-05/
-
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
(Hinzugefügt: 04.05.2021 um 05:32 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-pediatric-expansion-phase-3-clinical-trial
-
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
(Hinzugefügt: 15.04.2021 um 06:15 Uhr)
https://apnews.com/press-release/pr-newswire/business-technology-public-health-products-and-services-coronavirus-pandemic-273d480f2e6383e1a1eea31b661946fd
-
Novavax says supply shortages delaying full-speed production of its COVID-19 vaccine
(Hinzugefügt: 14.04.2021 um 07:03 Uhr)
https://www.reuters.com/article/us-health-coronavirus-novavax-idUSKBN2C013Z
-
Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
(Hinzugefügt: 08.04.2021 um 06:22 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2103740
-
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
(Hinzugefügt: 06.04.2021 um 06:57 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-initiates-covid-19-vaccine-clinical-trial-crossover
-
Exclusive: Novavax delays EU vaccine supply deal amid production problems - source
(Hinzugefügt: 25.03.2021 um 20:16 Uhr)
https://www.reuters.com/article/us-health-coronavirus-eu-novavax-exclusi-idUSKBN2BH2GY
-
SARS-CoV-2: Hohe Schutzwirkung des Proteinimpfstoffs von Novavax gegen südafrikanische Variante abgeschwächt
(Hinzugefügt: 13.03.2021 um 08:05 Uhr)
https://www.aerzteblatt.de/nachrichten/122002/SARS-CoV-2-Hohe-Schutzwirkung-des-Proteinimpfstoffs-von-Novavax-gegen-suedafrikanische-Variante-abgeschwaecht
-
Novavax vaccine 96% effective against original coronavirus, 86% vs British variant in UK trial
(Hinzugefügt: 12.03.2021 um 05:44 Uhr)
https://www.reuters.com/article/uk-health-coronavirus-vaccines-novavax-idUSKBN2B32ZI
-
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
(Hinzugefügt: 12.03.2021 um 05:41 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-confirms-high-levels-efficacy-against-original-and
-
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
(Hinzugefügt: 04.03.2021 um 08:23 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.25.21252477v1
-
Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults
(Hinzugefügt: 02.03.2021 um 07:01 Uhr)
https://www.medrxiv.org/content/10.1101/2021.02.26.21252482v1
-
Novavax COVID-19 shot could be cleared for U.S. use by May: CEO
(Hinzugefügt: 02.03.2021 um 06:45 Uhr)
https://www.reuters.com/article/us-novavax-results-idUSKCN2AT3MD
-
Novavax expects U.S. trial data for COVID-19 vaccine at start of April
(Hinzugefügt: 25.02.2021 um 19:49 Uhr)
https://www.reuters.com/article/us-health-coronavirus-novavax-vaccine-idUSKBN2AO2HC
-
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan Read more: http://m.digitaljournal.com/pr/4984230#ixzz6nNNBMHAh
(Hinzugefügt: 24.02.2021 um 08:35 Uhr)
http://m.digitaljournal.com/pr/4984230
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
(Hinzugefügt: 23.02.2021 um 08:45 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-completes-enrollment-prevent-19-covid-19-vaccine-pivotal
-
Novavax to provide 1.1 billion Covid-19 doses to low and middle income countries Read more at: https://www.deccanherald.com/international/novavax-to-provide-11-billion-covid-19-doses-to-low-and-middle-income-countries-953153.html
(Hinzugefügt: 20.02.2021 um 12:22 Uhr)
https://www.deccanherald.com/international/novavax-to-provide-11-billion-covid-19-doses-to-low-and-middle-income-countries-953153.html
-
Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine
(Hinzugefügt: 19.02.2021 um 10:23 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-memorandum-understanding-gavi-cumulative
-
Regulatory agencies start rolling review of Novavax’s Covid-19 vaccine
(Hinzugefügt: 09.02.2021 um 09:15 Uhr)
https://www.pharmaceutical-technology.com/news/rolling-review-novavax-vaccine/
-
Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
(Hinzugefügt: 05.02.2021 um 08:26 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-start-rolling-review-multiple-regulatory
-
Vaccine Not as Effective Against S. African Variant
(Hinzugefügt: 02.02.2021 um 20:34 Uhr)
https://www.webmd.com/vaccines/covid-19-vaccine/news/20210131/vaccine-not-as-effective-against-south-african-variant
-
Novavax submits coronavirus vaccine to Health Canada for approval
(Hinzugefügt: 01.02.2021 um 08:33 Uhr)
https://globalnews.ca/news/7610676/health-canada-novavax/
-
Novavax-Impfstoff: Vor allem die südafrikanische Variante mindert die Schutzwirkung gegen COVID-19
(Hinzugefügt: 31.01.2021 um 10:26 Uhr)
https://www.aerzteblatt.de/nachrichten/120667/Novavax-Impfstoff-Vor-allem-die-suedafrikanische-Variante-mindert-die-Schutzwirkung-gegen-COVID-19
-
Novavax expects to produce 150 million vaccine doses per month as early as May: CEO
(Hinzugefügt: 29.01.2021 um 22:33 Uhr)
https://www.reuters.com/article/us-health-coronavirus-vaccine-novavax-idUSKBN29Y2WP
-
J&J and Novavax Data
(Hinzugefügt: 29.01.2021 um 20:23 Uhr)
https://blogs.sciencemag.org/pipeline/
-
First evidence that COVID vaccines protect people against new variants
(Hinzugefügt: 29.01.2021 um 10:30 Uhr)
https://www.nature.com/articles/d41586-021-00268-9
-
Novavax meldet hohen Schutz vor Covid-19 – mit einem Haken
(Hinzugefügt: 29.01.2021 um 08:35 Uhr)
https://www.welt.de/politik/ausland/article225253245/Novavax-Neuer-Impfstoff-soll-hohen-Schutz-vor-Covid-19-bieten-mit-einem-Haken.html
-
Geringere Effizienz bei Mutante Novavax-Impfstoff zu 89 Prozent wirksam
(Hinzugefügt: 29.01.2021 um 08:31 Uhr)
https://www.n-tv.de/panorama/Novavax-Impfstoff-zu-89-Prozent-wirksam-article22324500.html
-
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
(Hinzugefügt: 29.01.2021 um 08:16 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
-
Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine
(Hinzugefügt: 23.01.2021 um 09:37 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-and-government-canada-finalize-advance-purchase
-
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
(Hinzugefügt: 31.12.2020 um 11:31 Uhr)
https://www.nih.gov/news-events/news-releases/phase-3-trial-novavax-investigational-covid-19-vaccine-opens
-
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico
(Hinzugefügt: 28.12.2020 um 18:59 Uhr)
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-initiation-prevent-19-pivotal-phase-3-efficacy
-
EU verhandelt mit US-Pharmakonzern Novavax über 100 Millionen Dosen Impfstoff
(Hinzugefügt: 20.12.2020 um 09:30 Uhr)
https://www.aerzteblatt.de/nachrichten/119558/EU-verhandelt-mit-US-Pharmakonzern-Novavax-ueber-100-Millionen-Dosen-Impfstoff
-
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
(Hinzugefügt: 12.12.2020 um 08:54 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2026920